Abstract 10977: Trends and Persistent Disparities in Hypertrophic Cardiomyopathy-Related Mortality in the United States: A Nationwide Analysis from 1999 to 2024
Abstract
Background: Hypertrophic cardiomyopathy (HCM) is a cardiac disorder associated with heart failure and sudden cardiac death. While advances in diagnosis and management have improved outcomes, contemporary national mortality trends and disparities remain incompletely understood. This study evaluates temporal trends in HCM-related mortality in the United States. Materials and Methods: We performed a retrospective analysis of the CDC WONDER Underlying Cause of Death database from 1999 to 2024. HCM-related deaths were identified using International Classification of Diseases (ICD-10) codes I42.1 and I42.2 as the underlying cause of death. The analysis was restricted to adults aged ≥25 years. Age-adjusted mortality rates (AAMRs) per 100,000 population were used. Temporal trends were assessed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC), with statistical significance defined as p<0.05. Results: A total of 25,945 HCM-related deaths were identified between 1999 and 2024. The AAMR declined from 0.7 in 1999 to 0.4 in 2024, corresponding to a significant overall decrease (AAPC –2.7%), although a non-significant upward trend was observed from 2018 to 2024. Mortality rates were higher among males; however, both sexes demonstrated overall declining trends, with a greater reduction in males (AAPC –3.67%) than females (AAPC –2.05%). Despite this overall decline, females demonstrated a statistically significant increase in mortality from 2015 to 2024 (APC 3.41%, p<0.05). By race/ethnicity, the highest mortality rates were observed among Non-Hispanic Black or African American individuals, who were the only group demonstrating a recent statistically significant increase from 2015 to 2024 (APC 3.18%). Non-Hispanic White individuals had the next highest mortality burden, while Hispanic populations experienced the greatest decline (AAPC –4.01%). Also, mortality rates were higher among individuals aged ≥65 years, with a recent statistically significant increase observed from 2020 to 2024 (APC 7.68%, p<0.05). Regionally, the West had the highest mortality rates in 1999 and demonstrated the greatest decline over time (AAPC –4.00%). By urbanization, mortality was highest in large central metropolitan areas in 1999, which also showed the most pronounced reduction (AAPC –6.2%). State-level analysis revealed higher mortality burdens in states such as California and Oregon. Conclusions: HCM-related mortality in the United States has declined significantly over the past two decades, likely reflecting advances in diagnosis, risk stratification, and management. However, recent increasing mortality trends in certain subgroups, particularly females, older adults, and Black individuals, highlight persistent disparities and the need for targeted interventions and specialized cardiovascular care for these groups.